AB
FULC icon

Amalgamated Bank’s Fulcrum Therapeutics FULC Stock Holding History

Amalgamated Bank’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,353
Closed -$15K – 2086
2025
Q4 		$15K Sell
1,353
-794
-37% -$8.08K ﹤0.01% 2242
2025
Q3 		$20K Hold
2,147
– – ﹤0.01% 2122
2025
Q2 		$15K Hold
2,147
– – ﹤0.01% 2236
2025
Q1 		$6K Hold
2,147
– – ﹤0.01% 2584
2024
Q4 		$10K Hold
2,147
– – ﹤0.01% 2428
2024
Q3 		$8K Hold
2,147
– – ﹤0.01% 2546
2024
Q2 		$13K Buy
+2,147
New +$16.3K ﹤0.01% 2301
2023
Q2 		– Sell
-5,054
Closed -$14K – 3064
2023
Q1 		$14K Sell
5,054
-670
-12% -$6K ﹤0.01% 2754
2022
Q4 		$42K Buy
5,724
+1,696
+42% +$11.1K ﹤0.01% 2499
2022
Q3 		$33K Hold
4,028
– – ﹤0.01% 2628
2022
Q2 		$20K Buy
4,028
+704
+21% +$6.88K ﹤0.01% 2851
2022
Q1 		$79K Buy
+3,324
New +$47K ﹤0.01% 2289

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Amalgamated Bank's FULC Position: Q1 2026 in Review

Amalgamated Bank sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 1,353 shares — an estimated $15K sold.

Amalgamated Bank first reported a position in FULC in Q1 2022 and held it in 12 quarters. The position peaked at $79K in Q1 2022. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Amalgamated Bank reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,353 Fulcrum Therapeutics shares in Q1 2026, an estimated $15K.
  • Amalgamated Bank first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's Fulcrum Therapeutics position peaked at $79K in Q1 2022.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.